Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis

• DOI: 10.1038/srep22251
• Publication Date: 2016-02-25T10:26:14Z
• Authors: Takaomi Kessoku; Kento Imajo; Yasushi Honda; Takayuki Kato; Yuji Ogawa; Wataru Tomeno; Shingo Kato; Hironori Mawatari; Koji Fujita; Masato Yoneda; Yoji Nagashima; Satoru Saito; Koichiro Wada; Atsushi Nakajima
• Keywords: Steatosis; Steatohepatitis

The natural polyphenol compound resveratrol (RSV) is considered to have a broad spectrum of beneficial biological activities upon human health. However, the exact effect RSV on steatosis (a phenotype non-alcoholic fatty liver [NAFL]) or fibrosis and inflammation (major phenotypes steatohepatitis [NASH]) not known. Our data showed that administration (2 20 mg/kg/day) did suppress in high-fat diet-induced model NAFL mice. In contrast, identical concentrations dramatically inhibited low-dose lipopolysaccharide-induced NASH. These suggested administration-mediated improvement was due inhibition LPS reactivity controlled by CD14 expression Kupffer cells. findings suggest could be candidate agent for treatment